Breakthroughs in hepatitis C research: from discovery to cure
MP Manns, B Maasoumy - Nature reviews Gastroenterology & …, 2022 - nature.com
In the 1970s, an unknown virus was suspected for documented cases of transfusion-
associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious …
associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious …
EASL clinical practice guidelines: management of hepatocellular carcinoma
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …
EASL recommendations on treatment of hepatitis C: final update of the series☆
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …
EASL recommendations on treatment of hepatitis C 2016
European Association for The Study of The Liver - Journal of hepatology, 2017 - Elsevier
Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy
M Reig, Z Mariño, C Perelló, M Iñarrairaegui… - Journal of …, 2016 - Elsevier
Background & Aims The success of direct-acting antivirals (DAA) against hepatitis C is a
major breakthrough in hepatology. Until now, however, there are very few data on the effect …
major breakthrough in hepatology. Until now, however, there are very few data on the effect …
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression
Background & Aims The risk of hepatocellular carcinoma (HCC) occurrence or recurrence
following direct-acting antiviral (DAA) hepatitis C virus (HCV) therapy remains unclear. The …
following direct-acting antiviral (DAA) hepatitis C virus (HCV) therapy remains unclear. The …
EASL recommendations on treatment of hepatitis C 2018
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …
Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis
MCM Cheung, AJ Walker, BE Hudson, S Verma… - Journal of …, 2016 - Elsevier
Background & Aims Direct-acting antivirals have become widely used for patients with
chronic hepatitis C virus infection with decompensated cirrhosis. Virological responses are …
chronic hepatitis C virus infection with decompensated cirrhosis. Virological responses are …
[PDF][PDF] Projections of primary liver cancer to 2030 in 30 countries worldwide
Primary liver cancer (PLC) is the sixth most common cancer worldwide and the second most
common cause of cancer death. Future predictions can inform health planners and raise …
common cause of cancer death. Future predictions can inform health planners and raise …
Quantitative elastography methods in liver disease: current evidence and future directions
Chronic liver diseases often result in the development of liver fibrosis and ultimately,
cirrhosis. Treatment strategies and prognosis differ greatly depending on the severity of liver …
cirrhosis. Treatment strategies and prognosis differ greatly depending on the severity of liver …